Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.71 |
| ▸ | RARB | P10826 | 2/20 | 0.61 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | MLNR | O43193 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6558279 | 1.00 | LTA4H (0.71) | LTA4HRARBKCNA3TSHRRECQL | |
| SCHEMBL2487712 | 1.00 | LTA4H (0.71) | LTA4HRARBKCNA3TSHRRECQL | |
| SCHEMBL2485485 | 1.00 | LTA4H (0.71) | LTA4HRARBKCNA3TSHRRECQL | |
| SCHEMBL28049795 | 0.94 | LTA4H (0.70) | LTA4HRARBKCNA3TSHRRECQL | |
| SCHEMBL10456457 | 0.94 | LTA4H (0.70) | LTA4HRARBKCNA3TSHRRECQL | |
| SCHEMBL7241377 | 0.94 | LTA4H (0.74) | LTA4HRARBKCNA3TSHRRECQL | |
| SCHEMBL969026 | 0.92 | LTA4H (0.68) | LTA4HRARBKCNA3TSHRMLNR | |
| SCHEMBL9407088 | 0.92 | LTA4H (0.68) | LTA4HRARBKCNA3TSHRMLNR | |
| SCHEMBL2485877 | 0.92 | LTA4H (0.68) | LTA4HRARBKCNA3TSHRMLNR | |
| SCHEMBL2484231 | 0.92 | LTA4H (0.68) | LTA4HRARBKCNA3TSHRMLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110072856-B | Process for producing alpha-hydroxycarboxylic acid dimer cyclic ester | 株式会社吴羽 | 2022-03-15 | — | — | CN | disclosed |
| CN-111699179-B | Method for producing cyclic ester | 株式会社吴羽 | 2021-09-17 | — | — | CN | disclosed |
| CN-111741953-B | Method for producing glycolide | 株式会社吴羽 | 2021-05-28 | — | — | CN | disclosed |
| CN-111757873-A | Method for producing glycolide | 株式会社吴羽 | 2020-10-09 | — | — | CN | disclosed |
| CN-111741953-A | Method for producing glycolide | 株式会社吴羽 | 2020-10-02 | — | — | CN | disclosed |
| CN-111741952-A | Method for producing glycolide | 株式会社吴羽 | 2020-10-02 | — | — | CN | disclosed |
| CN-111699179-A | Method for producing cyclic ester | 株式会社吴羽 | 2020-09-22 | — | — | CN | disclosed |
| WO-2019181340-A1 | GLYCOLIDE PRODUCTION METHOD | 株式会社クレハ | 2019-09-26 | — | — | WO | disclosed |
| WO-2019181298-A1 | METHOD FOR PRODUCING GLYCOLIDE | 株式会社クレハ | 2019-09-26 | — | — | WO | disclosed |
| WO-2019181516-A1 | GLYCOLIDE PRODUCTION METHOD | 株式会社クレハ | 2019-09-26 | — | — | WO | disclosed |
| EP-2377858-B1 | METHOD FOR PRODUCING GLYCOLIDE | KUREHA CORP (JP) | 2014-04-30 | — | — | EP | disclosed |
| US-20120289713-A1 | METHOD FOR PRODUCING GLYCOLIDE | KUREHA CORPORATION (JP) | 2012-11-15 | — | — | US | disclosed |
| US-20110263875-A1 | Production Process of Glycolide | KUREHA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2377858-A1 | METHOD FOR PRODUCING GLYCOLIDE | Kureha Corporation (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-7812181-B2 | Process for producing glycolide and glycolic acid oligomer for production of glycolide | KUREHA CORPORATION (JP) | 2010-10-12 | — | — | US | disclosed |
| US-20070293653-A1 | depolymerizing polyglycolic acid by heating in an organic solvent; system is controlled to suppress efffective concentration of impurities (ammonia, amines or amides, methoxyacetic acid and diglycolic acid); high purity glycolide starting material for polyglycolic acid | KUREHA CORPORATION (JP) | 2007-12-20 | — | — | US | disclosed |
| EP-1310496-B1 | PROCESS FOR THE PREPARATION OF CYCLIC ESTERS AND METHOD FOR PURIFICATION OF THE SAME | KUREHA CORP (JP) | 2006-12-06 | — | — | EP | disclosed |
| US-6916939-B2 | Process for the preparation of cyclic esters and method for purification of the same | KUREHA KAGAKU KOGYO K.K. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20030191326-A1 | Process for the preparation of cyclic esters and method for purification of the same | KUREHA CORPORATION (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1310496-A1 | PROCESS FOR THE PREPARATION OF CYCLIC ESTERS AND METHOD FOR PURIFICATION OF THE SAME | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191326-A1 | Process for the preparation of cyclic esters and method for purification of the same | CEL, CETP, MCCC2 | LTA4H 908/4885RARB 4616/4885KCNA3 3799/4885 |
| US-20110263875-A1 | Production Process of Glycolide | RPN2, RPN1, DDOST | LTA4H 732/4885RARB 1670/4885KCNA3 4389/4885 |
| US-20120289713-A1 | METHOD FOR PRODUCING GLYCOLIDE | DDOST, MAGT1, UGCG | LTA4H 2545/4885RARB 3243/4885KCNA3 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.